Regulation of the pharmaceutical industry: promoting health or protecting wealth? - Wikidata - awgldk - TriplyDB

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

http://www.wikidata.org/entity/Q55553073

about

sameAs

The importance of being NICE.How NICE turned into a Teletubby.

P2860

Q50779435-99DD70CB-FFE1-4796-A888-D5FCF71CF067 Q55218401-58E632F7-4A06-46F8-AA74-AFF4CA6CFE75

P2860

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

http://www.wikidata.org/entity/Q55553073

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@en

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@nl

type

label

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@en

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@nl

prefLabel

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@en

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@nl

P1433

Q55553073-FE0099BD-354F-4329-85EC-C97612660203

P1476

Q55553073-FA35B602-BC6F-485A-B12D-81CF5923C301

P2093

Q55553073-6A83E3E5-F09D-4C0A-9B45-C6B69554589D

P2860

Q55553073-10EA6D15-98A9-4555-A826-06907B990DB5

Q55553073-3A9193BA-717A-40DD-8BCE-10B9D1E12133

Q55553073-4EBDF6D0-233A-4249-9B2A-EB0D233D4817

Q55553073-4F238EEB-ADAC-4ACD-A07F-389CDDEBCCF9

Q55553073-6B9E0D33-914F-4650-B1FA-98C22AB8BB0B

Q55553073-6F084AAA-A50E-4065-BD2B-5B8A0C9E5D69

Q55553073-95F57F65-4B08-46B0-BB63-8F8C4DE7DD96

Q55553073-F4C1EC36-5A92-40A9-9A5C-30AA22A084D4

P304

Q55553073-DD2FB928-17E4-458A-A484-4591A7FCB1B5

P31

Q55553073-DB322F35-6C4F-4984-8A13-B099C5C13EF8

P356

Q55553073-8B4AA2EB-C960-41EA-A9CD-0B9C0053E1F7

P407

Q55553073-A0BD38C3-C3E4-46AC-9E1E-C66EAF1B77AC

P433

Q55553073-5A53F578-D59D-4D8B-A8AF-F1BFB38A268F

P478

Q55553073-C3B76B64-C09C-4DFA-B16C-09D6F3999773

P50

Q55553073-1991DB99-F284-4452-99B2-217A995891B1

P577

Q55553073-81A54513-4B8C-43FC-8D7D-04237CC37F5E

P5875

Q55553073-38DD4E42-50C2-404D-82C8-8CC64BE6A3DB

P698

Q55553073-9DFA4B43-4955-4202-8E03-38B8522271BA

P932

Q55553073-C19DB955-060B-4145-8AA8-05A688E0B787

P356

0141076814568299

P1433

Journal of the Royal Society of Medicine

P1476

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

@en

P2093

Alan Maynard

http://www.w3.org/2001/XMLSchema#string

P2860

A Clearer View of Evidence in Treating Macular Degeneration: Off-Label Policies and Independent Research

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Are clinical trial data shared sufficiently today? No.

International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.

Excess in the pharmaceutical industry.

P304

220-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0141076814568299

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275661723

http://www.w3.org/2001/XMLSchema#string

P698

25922427

http://www.w3.org/2001/XMLSchema#string

P932

4480556

http://www.w3.org/2001/XMLSchema#string